Porcine IFN-gamma Antibody from MABTECH AB
Search, find, compare suppliers for anti-Porcine IFN-gamma antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Porcine IFN-gamma |
| Clone | pIFNγ-I |
| Host Species | Mouse |
| Reactive Species | pig |
| Isotype | IgG1 |
| Format | unconjugated |
| Size | ?1 mg |
| Concentration | n/a |
| Applications | ELISpot, ELISA |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: Native porcine IFN-γ. Recombinant porcine IFN-γ produced in E.coli and human cells, but not yeast cells. This monoclonal antibody enables sensitive and specific detection of porcine IFN-γ in immunoassays such as ELISA and ELISpot. We recommend pIFNγ-I as capture antibody in ELISA and ELISpot in combination with biotinylated detection antibody P2C11. |
| Immunogen | n/a |
| Other Names | Interferon |
| Gene, Accession # | Gene ID: 396991 |
| Catalog # | 3130-3-1000 |
| Price | please inquire |
| Order / More Info | Porcine IFN-gamma Antibody from MABTECH AB |
| Product Specific References | Stadler, J., et al. (2018). Safety and immune responses after intradermal application of Porcilis PRRS in either the neck or the perianal region. PLoS ONE. (http://www.ncbi.nlm.nih.gov/pubmed/30192831)Suarez, M., et al. (2017). A single dose of the novel chimeric subunit vaccine E2-CD154 confers early full protection against classical swine fever virus. Vaccine. (http://www.ncbi.nlm.nih.gov/pubmed/28688785)Sedlak, C., et al. (2014). IL-12 and IL-18 induce interferon-γ production and de novo CD2 expression in porcine γδ T cells. Developmental & Comparative Immunology. (http://www.ncbi.nlm.nih.gov/pubmed/25036760)Christiansen, D., et al. (2019). Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci Rep. (http://www.ncbi.nlm.nih.gov/pubmed/31239471)Herve, P. L., et al. (2016). Non-invasive epicutaneous vaccine against Respiratory Syncytial Virus: Preclinical proof of concept. J Control Release. (http://www.ncbi.nlm.nih.gov/pubmed/27720994) |
MABTECH AB
MABTECH AB
Box 1233
SE-131 28 Nacka Strand SWEDEN
P: +46 8 716 27 00
F: +46 8 716 27 01
mabtech@mabtech.com
http://www.mabtech.com
Profile of MABTECH AB
Return to Antibodies